Igc Pharma(NYSEMKT) IGC

IGC Pharma develops drugs and wellness products for people affected by Alzheimer’s disease. Its main drug candidate aims to reduce agitation in dementia patients. The company also offers wellness products and services for consumers and businesses.

What’s in the IGC Toolbox?

• Investigational Drugs (0% revenue): Experimental treatments for Alzheimer’s, including IGC-AD1 (in clinical trials) and TGR-63 (pre-clinical).
• White-Label Services (89.4% of revenue for the nine months ended December 31, 2024): Manufacturing and rebranding of wellness products for other companies.
• Wellness Products (10.7% of revenue for the nine months ended December 31, 2024): Consumer items like gummies, tinctures, and lotions, mainly for the U.S. market.
• AI Research Tools (0% revenue): Artificial intelligence models and software to improve Alzheimer’s research and clinical trials.
• Clinical Trial Services (0% revenue): Proprietary software and internal research organization to manage drug trials efficiently.

Growth and Expansion: The IGC Adventure

• Launched Phase 2 clinical trial for IGC-AD1 in 2023, expanding research scope in 2024.
• Introduced proprietary clinical trial software and internal research services in 2024.
• Entered the U.S. market, which accounted for 99.8% of revenue as of 2024.
• Won two awards in the PREPARE Challenge for Alzheimer’s prediction in 2024.
• Shifted focus from construction equipment (now inactive) to life sciences since 2022.

Why IGC Stands Out (Without the Lab Coat)

IGC focuses on Alzheimer’s with five drug candidates targeting different disease features. Its use of artificial intelligence and in-house trial management aims to cut costs and speed up research. The company holds 30 patent filings and generates most revenue from white-label wellness services.

Five Things You Need to Know

• Revenue was $941,000 for nine months ended December 2024, down 10% year-on-year.
• White-label services made up 89.4% of revenue in the same period.
• Gross margin was 49% for nine months ended December 2024, down from 54% prior year.
• Net loss was $5.9 million for nine months ended December 2024, improved from $10.1 million prior year.

Bottom Line

IGC has shifted from construction to life sciences, focusing on Alzheimer’s and wellness. The company relies on innovation and service diversification to support its evolving business model.